Virtual Library
Start Your Search
I. Chitapanarux
Author of
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-007 - Treatment Outcomes of Combine Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Single Institution Study (ID 3823)
14:30 - 14:30 | Author(s): I. Chitapanarux
- Abstract
Background:
Since 1990s, the standard treatment for locally advanced non-small cell lung cancer (NSCLC) has been changed because the treatment by adding chemotherapy to thoracic radiation (TRT) was proved to gain a survival benefit over TRT alone. We conducted this study to report the outcome of combination treatment along with determine the factors that effecting survival.
Methods:
Medical records of 1,325 NSCLC patients who treated with radiotherapy in our division during 2008 to 2013 were reviewed. The patient characteristics, the management characteristics and outcome data were recorded. Univariate and multivariate analysis were performed to identify the prognostic factor for overall survival.
Results:
A total of 103 patients were included in the analysis. With a median follow up time 13.27 months, these patients had a median overall survival (OS) time of 21.4 months (95%-CI 17.6-25.2 months) and median progression-free survival (PFS) time of 11.67 months (95%-CI 9.69-13.65 months). The 2-year OS and PFS rate were 34.0 and 21.4%, respectively. For the patients treated by concurrent and sequential chemoradiation, the 2-year OS rate were 31.0% and 37.8% (p=0.349) and the 2-year PFS rate were 24% and 20.6% (p=0.690), respectively. The multivariate analysis revealed that age (hazard ratio (HR) 1.68; 95% CI: 1.06 – 1.69) and stage (HR 2.13; 95% CI: 1.43 – 3.39) were significant prognostic factors for overall survival.
Conclusion:
The treatment of locally advanced NSCLC in our hospital is feasible and the outcomes are comparable to others. The results of concurrent chemoradiation may improve further by careful patient selection.
